Kort KC, Schiller HJ, Numann PJ. Hyperparathyroidism and pregnancy. Am J Surg. 1999;177(1):66-8. https://pubmed.ncbi.nlm.nih.gov/10037311. https://doi.org/10.1016/s0002-9610(98)00302-x.

Heath H 3rd, Hodgson SF, Kennedy MA. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med. 1980;302(4):189-93. https://pubmed.ncbi.nlm.nih.gov/7350459. https://doi.org/10.1056/NEJM198001243020402.

Shifrin A. Advances in diagnosis and management of primary hyperparathyroidism during pregnancy. Advances in treatment and management in surgical endocrinology. Elsevier Inc.; 2019.

Bollerslev J, Rejnmark L, Zahn A, et al. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). Eur J Endocrinol. 2022;186(2):R33-63. https://pubmed.ncbi.nlm.nih.gov/34863037. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789028. https://doi.org/10.1530/EJE-21-1044.

Bollerslev J, Marcocci C, Sosa M, Nordenström J, Bouillon R, Mosekilde L. Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol. 2011;165(6):851-64. https://pubmed.ncbi.nlm.nih.gov/21964961. https://doi.org/10.1530/EJE-11-0589.

Hassan-Smith ZK, Criseno S, Gittoes NJL. Mild primary hyperparathyroidism—to treat or not to treat? Br Med Bull. 2019;129(1):53-67. https://pubmed.ncbi.nlm.nih.gov/30576424. https://doi.org/10.1093/bmb/ldy042.

Bilezikian JP, Khan AA, Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94(2):335–9. https://pubmed.ncbi.nlm.nih.gov/19193908. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214274. https://doi.org/10.1210/jc.2014-1413.

Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011;253(3):585-91. https://pubmed.ncbi.nlm.nih.gov/21183844. https://doi.org/10.1097/SLA.0b013e318208fed9.

Horjus C, Groot I, Telting D, et al. Cinacalcet for hyperparathyroidism in pregnancy and puerperium. J Pediatr Endocrinol Metab. 2009;22(8):741-9. https://pubmed.ncbi.nlm.nih.gov/19845125. https://doi.org/10.1515/jpem.2009.22.8.741.

Vera L, Oddo S, Di Iorgi N, Bentivoglio G, Giusti M. Primary hyperparathyroidism in pregnancy treated with cinacalcet: A case report and review of the literature. J Med Case Rep. 2016;10(1):361. https://pubmed.ncbi.nlm.nih.gov/27998296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175373. https://doi.org/10.1186/s13256-016-1093-2.

Arshad MF, Arambewela MH, Bennet WM, Sterrenburg M, Balasubramanian SP. Primary hyperparathyroidism in pregnancy: Experience of a tertiary centre. Surg Today. 2023;53(4):470-5. https://pubmed.ncbi.nlm.nih.gov/36107253. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042935. https://doi.org/10.1007/s00595-022-02583-8.

Rey E, Jacob C-E, Koolian M, Morin F. Hypercalcemia in pregnancy – a multifaceted challenge: Case reports and literature review. Clin Case Rep. 2016;4(10):1001-8. https://pubmed.ncbi.nlm.nih.gov/27761256. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054480. https://doi.org/10.1002/ccr3.646.

Joint Formulary Committee. Calcitonin (salmon). British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; [cited 2023 Feb 21]. https://bnf.nice.org.uk/drugs/calcitonin-salmon/.

Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can. 2008;30(12):1146-8. https://pubmed.ncbi.nlm.nih.gov/19175968. https://doi.org/10.1016/S1701-2163(16)34026-9.

Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60(2):68-73. https://pubmed.ncbi.nlm.nih.gov/10440778. https://doi.org/10.1002/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H.

DiMarco AN, Meeran K, Christakis I, et al. Seventeen cases of primary hyperparathyroidism in pregnancy: A call for management guidelines. J Endocr Soc. 2019;3(5):1009–21. https://pubmed.ncbi.nlm.nih.gov/31065618. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497920. https://doi.org/10.1210/js.2018-00340.

Hui E, Osakwe O, Teoh TG, Tolley N, Robinson S. Three case reports of maternal primary hyperparathyroidism in each trimester and a review of optimal management in pregnancy. Obstet Med. 2010;3(1):33–7. https://pubmed.ncbi.nlm.nih.gov/27582838. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989765. https://doi.org/10.1258/om.2009.090040.

Schnatz PF, Thaxton S. Parathyroidectomy in the third trimester of pregnancy. Obstet Gynecol Surv. 2005;60(10):672–82. https://pubmed.ncbi.nlm.nih.gov/16186784. https://doi.org/10.1097/01.ogx.0000180889.23678.fb.

Norman J, Politz D, Politz L. Hyperparathyroidism during pregnancy and the effect of rising calcium on pregnancy loss: A call for earlier intervention. Clin Endocrinol (Oxf). 2009;71(1):104–9. https://pubmed.ncbi.nlm.nih.gov/19138316. https://doi.org/10.1111/j.1365-2265.2008.03495.x.